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Background: HIV-associated dementia (HAD) is the most common dementia type in young adults less than
40 years of age. Although the neurotoxins, oxidative/metabolic stress and impaired activity of neurotrophic factors
are believed to be underlying reasons for the development of HAD, the genomic basis, which ultimately defines
the virus-host interaction and leads to neurologic manifestation of HIV disease is lacking. Therefore, identifying HIV
fingerprints on the host gene machinery and its regulation by microRNA holds a great promise and potential for
improving our understanding of HAD pathogenesis, its diagnosis and therapy.
Results: A parallel profiling of mRNA and miRNA of the frontal cortex autopsies from HIV positive patients with and
without dementia was performed using Illumina Human-6 BeadChip and Affymetrix version 1.0 miRNA array,
respectively. The gene ontology and pathway analysis of the two data sets showed high concordance between
miRNA and mRNAs, revealing significant interference with the host axon guidance and its downstream signalling
pathways in HAD brains. Moreover, the differentially expressed (DE) miRNAs identified in this study, in particular
miR-137, 153 and 218, based on which most correlations were built cumulatively targeted neurodegeneration
related pathways, implying their future potential in diagnosis, prognosis and possible therapies for HIV-mediated
and possibly other neurodegenerative diseases. Furthermore, this relationship between DE miRNAs and DE mRNAs
was also reflected in correlation analysis using Bayesian networks by splitting-averaging strategy (SA-BNs), which
revealed 195 statistically significant correlated miRNA-mRNA pairs according to Pearson’s correlation test (P<0.05).
Conclusions: Our study provides the first evidence on unambiguous support for intrinsic functional relationship
between mRNA and miRNA in the context of HIV-mediated neurodegeneration, which shows that neurologic
manifestation in HIV patients possibly occurs through the interference with the host axon guidance and its
downstream signalling pathways. These data provide an excellent avenue for the development of new generation
of diagnostic/prognostic biomarkers and therapeutic intervention strategies for HIV-associated neurodegeneration.
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HIV-associated dementia (HAD) is the most common
dementia type in young adults less than 40 years of age.
To date, the cumulative incidence of HAD is 25-38%,
and the prevalence is around 37% [1]. Although the
highly active antiretroviral therapy (HAART) has had
considerable success in preventing virus-mediated im-
mune collapse end-stage complications, the prevalence
of HIV-associated cognitive impairment appears to be
on the rise due to the increased life span of HIV+
population.
It is well recognized that host-virus interactions play a
crucial role in the occurrence and pathogenesis of HAD.
Microarray and high throughput genomic technologies
have greatly facilitated the examination of this inter-
action. A panoply of host genes have been shown to be
influenced by HIV infection that facilitate subversion
and manipulation of the host immune system during
HIV infection of the brain. To date, most studies explor-
ing HAD pathogenesis [2-6] have largely been confined
to cultured cells, cerebrospinal fluid (CSF) and animal
models, which can’t mimic and reveal the breadth of
in vivo cellular responses subverted and manipulated as
a consequence of HIV infection.
Recently, microRNAs (miRNAs), a class of small (20–
25 nucleotides) non-coding RNAs, have been recognized
as master post-transcriptional regulators of mRNAs [7]
due to their numerous targeting capabilities along with
their ability to form non-linear functionally viable gene
regulatory networks, which together have wide-ranging
effects on the control of host gene expression. In
addition, miRNAs are also involved in diverse processes,
which include neuronal development, cell differentiation,
synapse formation and neuronal plasticity [8,9]. Thus,
not surprisingly, miRNAs are significantly involved in
neurodegenerative diseases, such as Parkinson disease
(PD) [10], Alzheimer’s disease (AD) [11], Schizophrenia
[12-15], aggressive behaviour [16] and depression [17].
Further, miRNAs also play an important role in HIV-
host interaction [18]. HIV can even manipulate the ex-
pression of host neuronal genes, such as SNAP25 and
cell death-related genes, including caspase-6, via the
modulation of expression of selected microRNAs, which
might serve as key elements in gene regulatory networks
in HIV-associated neurobehavioral disorder [19-21].
To date, a joint study of the genome wide mRNA and
miRNA profiling based on HIV-infected brain tissue with
and without dementia is still lacking, although some indi-
vidual mRNA [22-25] and miRNA [26] profiling studies
based on human brain have been done. Therefore, our in-
novative approach has studied the utility of parallel
genome-wide mRNA and miRNA analysis in the native
frontal lobe post-mortem brain tissue from HIV patients
with and without dementia. This carries enormous valuein understanding gene expression in the context of HIV-
mediated neurodegeneration and its regulation through
miRNAs. This study has been designed with an objective
to comprehensively delineate host transcriptional pro-
gramming that occurs in concert with the regulatory miR-
NAs and to find how this interaction between mRNA and
miRNA tampers with neurodegenerative pathways and
dictates neurological manifestation of HIV disease. Here,
we examined the gene ontology and pathways of differen-
tially expressed (DE) mRNA in parallel with the global
gene targets of DE miRNAs. Moreover, we derived paired
functional correlation between mRNA and miRNA
expressions using splitting-averaging strategy (SA-BNs) to
demonstrate intrinsic functional relationship between
gene expression and its regulation. In light of these data
we believe that these results will not only facilitate a
greater understanding of HIV pathogenesis of the brain
and its neurological manifestation, but will also help de-
fine potential candidates for early detection and future
therapy for neurodegeneration in HIV patients and related
disorders.
Results
A snapshot of DE mRNA and miRNA profiles between
HAD and HIV non-demented brains
In order to identify the mRNA and miRNA, which may
contribute to the pathogenesis of HAD, a parallel
genome-wide mRNA and miRNA profiling of the frontal
cortex from HIV patients with and without dementia
was performed.
GenomeStudio was used to analyse the normalized
mRNA dataset. We observed 468 statistically significant
candidate genes that were differentially expressed be-
tween two groups (P<0.05) (see Additional file 1).
Among them, 432 genes were down regulated and 36
genes were up regulated (P<0.05), and 203 of 432 genes
dysregulated greater than 1.5-fold change. To determine
the similarity of global gene expression between samples
and also in relation to the DE genes, hierarchical cluster-
ing was performed and generated using GenomeStudio
(Additional file 2A). The HAD group formed an inde-
pendent cluster away from the HIV non-dementia
group, with the exception of one sample with dementia
(neurological status less than 2) which clustered together
with the HIV non-dementia group. Not surprisingly, the
HIV non-dementia group clustered together with HIV
negative control due to the absence of neuropathological
changes and the absence of actively replicating HIV,
which is consistent with a previous study [27] and our
own study [28].
The analysis of miRNA data using GeneSpring identi-
fied 68 miRNA that were significantly differentially
expressed in HAD and HIV non-dementia cortex
(Additional file 3). Among them, 49 miRNAs were down
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dysregulated greater than 2 fold. Hierarchical clustering
was carried out to demonstrate patterns of miRNA ex-
pression profiling between two groups (Additional file
2B), which was consistent with our mRNA hierarchical
clustering. TargetScan was used to predict the gene tar-
gets of DE miRNAs, because it is the most advanced,
respected, widely used and relatively conservative data-
base in comparison to other databases (Additional file
4). In addition, we have carried out a low and high strin-
gency G-seed search for miR-137, miR-153 and miR-218
targets based on a minimal free energy (MFE) ¾ -10 and
¾-14, respectively (Additional file 5). Furthermore, these
predictions were made in the context of changes in gene
expression observed in the same RNA.
Functional annotation of the mRNA DE genes and
miRNA target genes was carried out in Database for An-
notation, Visualization and Integrated Discovery (DAVID)
together with extensive literature search. These mRNA
DE genes were significantly associated with biological pro-
cesses, such as cell death/cell cycle, neuronal processes,
metabolism, transcriptional regulation, protein modifica-
tion, signal transduction, and response to virus/stress, as
shown in Figure 1A. In addition, according to cellularFigure 1 Representation of gene ontology cellular components and b
representation of biological processes and cellular components, where eac
component from the set of significant biological processes and cellular com
retrieved from gene ontology analysis in DAVID. A. Biological processes of
components of mRNA profiles. D. Cellular components of miRNA profiles.components distribution, 29% of genes fell into neuronal-
related components, such as axon, neuron projection,
and dendrite (Figure 1C). Furthermore, Gene Set Enrich-
ment Analysis (GSEA) was also used to examine signifi-
cantly enriched GO (gene ontology) gene sets comparing
the normalized data of the entire 48,701 gene transcripts
from HAD and HIV non-dementia brains to 1454 GO
gene sets in GSEA Molecular Signatures Database
(MsigDB) [29]. Eight gene sets were found statistical sig-
nificantly enriched (P<0.05) in HIV non-dementia group
while no gene sets were significantly enriched in the
HAD group (indicating down regulation of those 8 gene
sets in the HAD group) (Additional file 6). Of the eight
enriched gene sets in the non-dementia group, four were
closely related to neurological and/or HIV disease: den-
drite (GO: 0030425) (Figure 2A), ATPase activity coupled
to transmembrane movement of ions (GO:0042625)
(Figure 2C), ATPase activity coupled to transmem-
brane movement of ions phosphorylative mechanism
(GO:0015662), and cytoskeleton dependent intracellular
transport (GO:0030705) (Figure 2E).
Functional annotation results of miRNA target genes
were consistent with that of mRNA results, but note-
worthy is that the miRNA target genes showed relativelyiological processes of mRNA and miRNA profiles. A pie chart
h part represents -log2 of the P-value of biological process and cellular
ponents. The total of -log2 of the P-value is 1. The P-values were
mRNA profiles. B. Biological processes of miRNA profiles. C. Cellular
Figure 2 (See legend on next page.)
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Figure 2 Enrichment plots and heat maps for the gene sets of dendrite, ATPase activity coupled to ion transmembrane movement
and cytoskeleton dependent intracellular transport generated by GSEA. (A) Enrichment plot for the gene set of dendrite. Y-axis: value of
the ranking metric; X-axis: the rank for all genes. Bottom: plot of the ranked list of all genes. Genes whose expression levels are most closely
associated with the HAD or HIV non-dementia group are located at the left or right edge of the list while genes from the gene set dendrite
within the ranked list are located at the middle. Top: the running enrichment score for the gene set as the analysis walks along the ranked list.
The score at the peak of the plot is the enrichment score (ES) for this gene set and those genes appear before or at the peak are defined as core
enrichment genes for this gene set. (B) Heat map of the core enrichment genes of the dendrite gene set, which contributes most to the ES.
Rows: gene; columns: samples. Range of colors (red to blue) indicates the range of expression values (high to low). (C) Enrichment plot for the
gene set of ATPase activity coupled to ion transmembrane movement. (D) Heat map of the core enrichment genes of the gene set ATPase
activity coupled to ion transmembrane movement. (E) Enrichment plot for the gene set of cytoskeleton dependent intracellular transport. (F)
Heat map of the core enrichment genes of the gene set cytoskeleton dependent intracellular transport.
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components, which could be attributed to the ability of
single miRNA to have numerous mRNA targets, therefore
further validation might be needed to precise the specifi-
city. Cellular components of miRNA target genes are
mainly distributed in cellular (61%) and neuronal related-
structures (19%)(Figure 1D), but they display scattering
into ion channel, actin cytoskeleton, tight junction, tran-
scription factor complex and chromatin, which concur
with our mRNA results. For instance, we found significant
dysregulation of genes in microtubule assembly (MAP4
and EML3), microtubule nucleation (TUBGCP6), cyto-
skeleton movement (SPTBN1) and microtubule
stabilization (CALD1). In regards to ion channel genes,
we found the upregulation of genes related to ion trans-
port or ion channel, including Ca2+, Cl-, Na+, K+, Cu2+,
Zn2+ and glutamine transport. Especially, the genes
involved in Ca2+, Na+ and glutamine transport changed
greater than 1.5 fold, the dysregulation of which is known
to play a significant role in pathophysiology of neurode-
generative diseases as discussed in subsequent sections.
We also found more than 20 genes dysregulated in tran-
scriptional regulation process, and similarly, the biological
process of small percentage of miRNA target genes fall
into cell adhesion, tissue/embryonic development, learn-
ing, and chromatin modification etc. (Figure 1B). Al-
though they were not dominant, they all can play a very
important role in neurological degeneration [30-33].
Quantitative real time RT-PCR corroboration of mRNA and
miRNA array dataset
In order to confirm and validate the data obtained by both
data sets, we analysed 11 DE genes and 6 DE miRNAs and
1 non-changed miRNA using quantitative real time RT-PCR
on the same study sample set.
For mRNA, the quantitative real time RT-PCR for 9 of
the 11 genes was fully consistent with their microarray ex-
pression profiles and trends (P<0.05) (Figure 3A). The two
genes (AQP and HBB) for which the RT-PCR was not con-
sistent with the microarray were excluded from further ana-
lysis. This, in no way, compromises the interpretation of our
dataset.For miRNA, the quantitative RT-PCR for 7 of 7 miRNAs
was consistent with the trend seen in microarray analysis
(P<0.05) (Figure 3B and Additional file 7), which enhances
the confidence and shows the validity of our miRNA data
set and their gene targets defined herein.
Pathway analysis of DE mRNAs and miRNAs
DE gene list and DE miRNA target gene list were uploaded
to DAVID to explore functionally relevant pathways.
For mRNA, long-term potentiation, axon guidance and
signalling pathways (including MAPK signalling pathway,
calcium signalling pathway, Jak-STAT signalling pathway
and VEGF signalling pathway) stood out significantly. Not
surprisingly, we found 7 genes significantly dysregulated
in long-term potentiation pathway (CHP, CACNA1C,
ITPR1, MAP2K1, PPP1R12A, PPP3CA and RPS6KA1)
(Additional file 8). Among them, ITPR1 and PPP3CA
down regulated greater than 1.5-fold change. Axon guid-
ance pathway was significantly down regulated in HAD
versus non-demented patients with 9 down regulated
genes (CHP, EPHA4, EFNB2, SEMA3A, PLXND1,
SRGAP1, GSK3B, DPYSL2 and PPP3CA) (Figure 4).
Among them, EPHA4 was down regulated >2 fold, while
PLXND1, SRGAP1, PPP3CA were down regulated >1.5
fold. There were a total of 27 genes involved in signalling
pathway. We found that all the 12/27 genes in the MAPK
pathway were down regulated, including the key members
of the MAPK signalling pathway, such as MAP2K1,
MAP2K4, MAP3K11, RRAS2, RPS6KA1 and TAOK1.
Among them, TAOK1 was down regulated greater than 2
fold, while MAP2K4, MAP3K11, PLA2G4A and RRAS2
was dysregulated greater than 1.5 fold (Figure 5). Two key
proteins in the MAPK pathway, MAP2K2 (MEK2) and
MAP2K4 (JNK), were also further validated by western
blotting analysis using 4 samples from HAD and 4 sam-
ples from HIV non-dementia group, respectively. Both
proteins showed down-regulation in HAD brains, which
followed the same trend observed in our microarray ana-
lysis. MEK2 was recognized by p-MEK-1/2 antibody at 45
kDa (see Additional file 9). It was expressed slightly
weaker in HAD brains as opposed to HIV non-dementia
patients (FC=1.1, Additional file 9). Interestingly, this
Figure 3 Validation of mRNA and miRNA profiles using quantitative RT-PCR on the same sample set of microarray study. A. mRNA
profiles validation. B. miRNA profiles validation. Data was analysed using the 2-ΔΔCt method and results were plotted as fold differences of relative
expression normalized to house keeping gene (GAPDH) and Hs_RNU6B_3 individually. The data have been collected from the same RNA samples
from which mRNA and miRNA profiling have been done. All the data presented in this figure have significant P value of <0.05 as calculated by
Student's t-test.
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and non-dementia patients were compared (FC=1.7),
which indicates its significance in HAD pathogenesis.
MAP2K4 was recognized by JNK1/3 antibody at 46 kDa
(Additional file 9). It was downregulated in the HAD brain
as well (FC=1.5). There are 11 genes dysregulated in the
calcium signalling pathway, 7 in Jak-STAT signalling path-
way and 5 in VEGF signalling pathway (there are overlap-
ping genes across different signalling pathways). The
details were listed in Additional file 10, Additional file 11
and Additional file 12.
It is worth mentioning that most of the core-enriched
genes contributing to each individual gene set signifi-
cantly enriched in GSEA analysis fell into neurodegen-
erative disease related pathways, such as tight junction
KEGG pathway, neurodegenerative disease pathway,MAPK signalling pathway, axon guidance pathway, and
phosphorylative mechanisms/signalling pathway (for
details see in Figure 2B, D and F). These results are con-
sistent with our previous observations [34] and func-
tional annotation analysis, therefore further confirmed
the significant involvement of these pathways in HAD
pathogenesis.
For miRNA, a number of significantly involved path-
ways (P<0.05) were revealed, including signalling path-
ways, adhesion/junction, axon guidance, depression/
potentiation, apoptosis/cell cycle, inflammation-related
pathways, ubiquitin mediated proteolysis, and regulation
of actin cytoskeleton (Additional file 13). Notable was
that several pathways were targeted by more than 5 DE
miRNAs. For instance, the wnt-signalling pathway was
targeted by 10 DE miRNAs, the axon guidance pathway
Figure 4 Significantly down-regulated genes on axon guidance pathway in HAD brains compared to HIV non-dementia brains. Pathway
analysis has revealed the significant involvement of axon guidance molecules and their receptors in HAD brains. The genes, which were found to
differentially express between HAD versus non-demented patients in the current study are highlighted in green.
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nalling pathway, long-term potentiation pathway and
focal adhesion pathway by 7 DE miRNAs. Interestingly,
the DE hsa-miR-19a targeted all 6 pathways listed above,
whereas the DE hsa-miR-137, hsa-miR-153 and hsa-miR-
218 targeted 5 pathways, and the DE hsa-miR-323 and
hsa-miR-495 targeted 4 pathways (Additional file 13).
Following the incorporation of mRNA pathway and
GSEA analysis results, this is a highly comprehensive
dataset in the context of neurodegeneration and patho-
genesis. In addition, we also found several cancer-related
pathways significant as well, which were consistent with
the fact that viruses can trigger or be co-factor of cancers
and that a number of cancer genes are pro-inflammation,
a scenario also seen in HIV infection and in neurode-
generative process, where HIV initiates cascade of pro-
inflammatory mediators (cytokines, chemokines and
adhesion molecules) and upregulation of their respect-
ive genes during infection [35].
Correlation between expression levels of DE miRNAs
and DE mRNAs
We evaluated the significance levels of all possible corre-
lations between DE mRNAs and miRNAs using SA-BNs
[36]. We found 438 interactions with high confidence in
total. Among them, 195 were statistically significant(P<0.05), including 13 miRNA and 116 mRNA, whose
expression levels correlated with each other according to
Pearson’s correlation (P<0.05) (Figure 6). The Pearson's
correlation of miRNA-mRNA pairs vs. significant confi-
dence of interaction discovered by SA-BNs has been
shown in Figure 7. Interestingly, most of them correlated
positively although miRNAs were downregulated.
Among them, hsa-miR-137, hsa-miR-153, hsa-miR-299-
5p, hsa-miR-218 and hsa-miR-376a were outstanding
due to their functional correlation with numerous genes.
It is interesting to see that most of the miRNA are down
regulated in HAD versus HIV non-demented brains, and
positively correlated with their mRNA target, which is
supported by previous findings [37,38].
To validate this correlation further, miRNA mimic of
miR-137 and negative control treatments were carried
out. That led a significant decrease in expression levels
of NUFIB1, SLC, RNF, BAG4, SPRED, ZRANB at 24 h
after transfection (Figure 8), which are all the genes
negatively regulated by miR137 according to the correl-
ation network we found. This result added extra confi-
dence to our correlation network.
Discussion
This is the first joint study of whole-genome mRNA and
miRNA profiling using individual human brain RNA
Figure 5 Significantly down-regulated genes on MAPK pathway in HAD brains compared to HIV non-dementia brains. Pathway analysis
has revealed the significant involvement of MAPK pathway in HAD brains. The genes, which were found to differentially express between HAD
versus non-demented patients in the current study are highlighted in green. The rectangles represented members of Mitogen-activated protein
kinases family while the ovals are related genes involved in MAPK pathway.
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In this study, we initially compared mRNA and miRNA
data at the clustering, gene ontology (including cellular
components and biological processes), and pathway
levels. Following that, SA-BNs correlating miRNAs and
mRNAs by their expression levels were performed to
validate the accurate prediction of genes potentially tar-
geted by dysregulated miRNAs.
The clustering and gene ontology results showed ex-
cellent functional concordance between mRNA and
miRNA, demonstrating the significant involvement of
neuronal cellular components and biological processes
such as: signal transduction, transcriptional regulation,
metabolism, response to stimuli, cell cycle/apoptosis,
protein modification, neuronal processes and ion trans-
port, respectively. This intrinsic functional consistency
between miRNA and mRNA has given an extra power
to our findings in relation to understanding the genomic
basis of HIV neuropathogenesis and HIV-mediatedneurodegeneration. Moreover, the DE miRNAs were
more robust than their mRNA counterparts in providing
a comprehensive snapshot of cellular components and
biological processes involved in neuropathology and
neurodegeneration. Compared to DE miRNAs, DE
mRNAs could only predict elemental functional path-
ways and processes related to neuropathology. DE miR-
NAs revealed the participation of additional cellular
components (eg. ion channel, actin cytoskeleton, tight
junction) and biological processes (cell adhesion, tissue/
embryonic development, learning), which also concurs
with biological processes of mRNA. Interestingly, these
findings are consistent with study, which has been done
using CSF of HIVE patients [40]. The most plausible ex-
planation for the comprehensiveness of miRNA coverage
as compared to their mRNA counterpart is that a single
miRNA or the miRNAs belonging to the same family in
the cluster can target several hundred genes within a bio-






























































































































































































































































































































Figure 6 miRNA-mRNA correlation network. miRNA-mRNA correlation network discovered by SA-BNs, rendered in cytoscape [39]. In this
network, the miRNAs are demonstrated by diamond shape while mRNAs with circles. Upregulated miRNA are in red, while downregulated
miRNA are in green. Upregulated mRNAs are in pink, while downregulated are in light green. The positive correlated miRNAs and mRNAs are
connected by red line, while the negative correlations by blue lines.
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mRNA. Secondly, there are many other gene regulational
mechanisms apart from miRNA and together they can
compensate the effect of miRNA dysregulation to some
degree, consequently the miRNA regulation effect can
only be seen after certain stage of disease progression
when other mechanisms are not sufficient any more [41].
Pathway analysis of the joint mRNA and miRNA results
provided the first in vivo evidence of significant involve-
ment of axon guidance pathway and its downstream sig-
nalling pathways (such as MAPK signalling pathway and
Ca2+ signalling pathway, etc.) on both transcriptional level
and regulation level. Axon guidance pledges precise path
finding and defines their termination zones and synaptic
partners [42,43], which is fundamental to neuronal devel-
opment and networks. In addition, misrouted fibers havebeen shown in AD and PD’s brains [44]. Furthermore, it is
well known that HIV envelope glycoprotein (GP120) can
cause axonal degeneration [45] and recently axon damage
has been claimed as a key predictor of outcome in mul-
tiple neurological disorders, including HAD [46]. Axon
guidance pathway contains four prominent families of
ligands (ephrin, netrin, semaphorin and slit proteins), their
receptors and downstream signalling proteins. The role of
axon guidance pathway molecules in the maintenance and
plasticity of neural circuits has been reported [47]. More-
over, the variations (single-nucleotide polymorphisms) in
axon guidance pathway genes have been reported to pre-
dict PD outcomes [48]. Significantly, 9 of our DE miRNAs
have been found targeting this pathway according to Tar-
getScan results; and more importantly these results sup-
port previous observations with 3 out of 4 ligands/
Figure 7 Pearson's correlation of miRNA-mRNA pairs vs. significant confidences of their interactions discovered by SA-BNs. A: Depiction
of positive interactions from each miRNA. B: Pearson's correlation of miRNA-mRNA pairs vs. significant confidences of their interactions discovered
by SA-BNs. The X-axis shows the confidence of interactions, ranging from 0 (the least confident) to 1 (the most confident), while only the
statistical significant scale remains (P<0.05). The Y-axis shows the sample correlations of identified miRNA-mRNA pairs. The red and blue dots are
miRNA-mRNA pairs, which are correlated at the significant level (P<0.05). It shows that the identified interactions are largely correlated, either
negatively or positively, suggesting direct interactions and indirect interactions correspondingly. C: Depiction of negative interactions from each
miRNA ◊miR137 □miR153 OmiR218 ×miR299-5p *miR376a XmiR122 +miR592 –miR584 -Others.
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cluding ephrin(EPH) receptor A4 (EPHA4), netrin G2
(NTNG2), and semaphoring 3A (SEMA3A), strongly sug-
gesting the impairment of axon guidance pathway in
HAD brains in vivo.Moreover, our results highlight axon guidance down-
stream signalling pathways, which allow precise patterns
of connectivity within the CNS. For instance, the MAPK
pathway comes out significant in both our mRNA and
miRNA profiling. Studies have shown that the activation
Figure 8 Effect of the transfection of microRNA mimic of miR-137. A. Transfection of neuroblasts showing basal expression of miR-137,
based on which our experiments on miR-137 target genes were carried out. B. Column chart of fold changes of expression values (qRT-PCR)
between SH-SY5Y transfected with miR-137 mimic or miRNA mimic negative control. Values are based on fold change calculated from
2-ΔΔCt method. All the columns have significant P value of <0.05 as calculated by Student's t-test.
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tributes to netrin signalling in axon guidance [50]. Besides,
netrin-dependent axon outgrowth and orientation can be
antagonized by inhibition of ERK-1/2 [50]. The role of
MAPK pathway in HIV infection has also been well docu-
mented. For instance, it has been reported that the MAPK
pathway plays a crucial role in HIV-1 replication and viru-
lence [51] and is one of the transcriptional signatures in
HIV+ long-term non-progressors [52]. In addition, the
binding of HIV-1 GP120 to CD4 receptors on T cells can
activate the MAPK pathway and induce transcription ofcytokine and chemokine genes [53]. Interestingly, MAPK
pathway was targeted by 3 DE miRNAs and it includes 11
of our DE genes, such as RPS6KA1, FLNA, RRAS2, and
MAP2K4 etc., each of which play an important role in
MAPK signalling. MAPK signalling cross-talks with the
Jak-STAT signalling pathway at multiple levels. In mam-
mals, the Jak-STAT signalling pathway is the principal sig-
nalling mechanism for cytokines and growth factors and
therefore plays a key role in cell proliferation, differenti-
ation, cell migration and apoptosis. Supporting this rela-
tionship, Jak-STAT was highlighted in our analysis as well.
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egory (including STAT) and it was targeted by DE miR-
19a. Dysregulation of Jak signalling might result in inflam-
mation [54], which is commonly accepted as an important
mediator in the pathogenesis of neurodegeneration. VEGF
signalling pathway is another significant pathway revealed
by our results, and it closely links to MAPK signalling
pathway as well. Via activating MAPK signalling pathway,
VEGF can exert direct effect on multiple types of neuronal
cells, including neurons, astrocytes, and microglias [55].
VEGF also has been reported to be involved in vascular
permeability [56] and several studies have shown the po-
tential utility of inhibiting VEGF signalling pathway in re-
ducing BBB disruption [57,58]. Besides, Ca2+ can mediate
guidance receptor signalling in vitro [59] and change in
Ca2+ concentration can signal growth cone turning [60].
Equivalently, guidance cues can also trigger Ca2+ influx
and alteration in Ca2+ concentration or slope its gradient,
thereby influencing the outcome of growth cone behavior
(attraction or repulsion) [61,62]. Our studies have demon-
strated several genes related to Ca2+ transport/signalling
dysregulated, including ATP2B4, which play a critical role
in intracellular calcium homeostasis.
In addition, endocytosis is another critical aspect of
guidance receptor activation and signalling [59]. Nine of
our DE miRNAs were found targeting this pathway and
several key genes were found dysregulated. Efficient cell
detachment needs the endocytosis of the ephrin-Eph
complex, or even bidirectional endocytosis for ephrinB-
EphB-induced repulsive guidance. In addition, endocyto-
sis also plays a role in regulating the senstivity of the
growth cone correspondent to a repulsive cue. Again, 9
of 68 of our DE miRNAs targeted endocytosis pathway.
Our mRNA study also revealed dysregulation of Ras
related protein (RAB4B) and EHD protein (EHD4),
which are important components of endocytosis path-
way. We also found ADAM22 dysregulated, whose fam-
ily member ADAM10 has been reported to play a role in
converting initial adhesive interaction into repulsion and
therefore providing an effective strategy for axon detach-
ment and attenuation of signalling [63,64].
Further, our miRNA and mRNA Bayesian correlation ana-
lysis has provided an unambiguous snapshot of miRNA and
mRNA functional interactions and their biological signifi-
cance. Sophisticated Bayesian Structure learning approach
defines miRNA-mRNA interactions based on their relative
expression of all of these molecules in each condition. This
network-based approach identified these key interactions
with very high confidence. These interactions define the net-
work topography that is provided by Bayesian statistics and
is substantially more rigorous than individual correlations
that can be defined conventionally. These relationships,
therefore, are more likely to be meaningful at the system
level compared to reporter assay. We identified 195 positiveand negative statistically significant correlations (P<0.05) be-
tween our DE mRNAs and miRNAs. It strengthens the cor-
relation and shows the credibility of Bayesian analysis we
have performed for establishing this intrinsic functional rela-
tionship between mRNA and miRNA. Among them, two
thirds of functional correlations are from 5 DE miRNAs:
miR-137, 153, 218, 376a and 299-5p. They all changed
greater than 2 fold. Since all of them have been reported to
be involved in classical neurodegeneration, for instance,
miR-376a has been reported to mutate in Huntington’s dis-
ease (HD) brains [65]; miR-299-5p has been reported to be
dysregulated in multiple sclerosis (MS) brains [66] and more
interestingly, all of them have been shown to be dysregu-
lated in the AD brains [67]. In particular, miR-137, 153 and
218, which can target more than 5 neurodegeneration-
related pathways, implying their functional relevance to the
observations noted in this study. The miR-137 has been
shown to be enriched in neurons, especially within the den-
tate gyrus and the molecular layer of adult hippocampus
[68] and studies have shown that it plays an important role
in modulating neuronal cell proliferation and differentiation
[68-71]. Moreover, it has been shown to be genetically asso-
ciated with schizophrenia [48]. Recently, it has been shown
dysregulated in the CSF of HIVE patients [40], which is con-
sistent with the expression of miRNA-137 in the frontal cor-
tex in our study in HAD patients. In addition, the miR-218
is enriched in hippocampus [72] and altered miR-218 ex-
pression has been reported in HD and MS brains [66,73].
The miR-153 has been shown to play important role in AD
and PD pathogenesis [74,75]. It can downregulate the ex-
pression of APP protein in vivo, suggesting its possible role
in AD pathogenesis [74]. Moreover, it can regulate α-synu-
clein, which is the primary structural components of Lewy
bodies, indicating its role in PD pathophysiological process
[75]. The genes that correlated to are all involved in several
significant pathways discussed above. In particular, SPRED1,
MAP2K4 and DIRAS2, they all correlated with 3 out of 3
miRNAs (miR-137, 153 and 218) and they all appear to be
involved in MAPK signalling pathway, which strongly indi-
cate the participation of MAPK pathway in HAD pathogen-
esis and is consistent with our previous proteomic studies
[34].
Although our study is the first comprehensive parallel
genome-wide mRNA and miRNA profiling of HIV infected
human brains, there are still limitations: 1. In future, a bigger
sample size, blood and CSF samples will be needed to fur-
ther validate these findings, and confirm the clinical value of
this findings; 2. These findings are based on the whole
human brain cortex rather than specific cell types (eg. neu-
rons) due to lack of plausible and effective methodologies
for perfect cell separation. Although Laser Capture Micro-
dissection (LCM) is currently used in studying cell types,
there are significant limitations in profiling single cell type
[76]: A. Due to the minimum laser spot size (7.5 μm), it
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without contaminating fragments of adjacent cells. B. Due
to its suboptimal optical resolution on uncovered sections, it
will compromise cell borders distinction and result in cyto-
plasmic compartment loss, which is crucial for our mRNA
analysis. Although immunohistochemical (IHC) staining will
circumvent this problem to some degree, it is impossible to
recover cytoplasmic compartment precisely without con-
tamination. Moreover, IHC procedures, tissue fixation and
LCM capturing of cells dramatically affect RNA yield. C.
Sectioning will generate large number of attached fragments,
which might alter expression profiles greatly. In addition,
due to the lack of the cytoplasm or even the nucleus, the
genomic information will be considerably compromised.
Overall, our study provides a strong foundation and
durable framework for systematic large-scale studies on
HIV-infected adult brain to define functional genomic phe-
notypes of neurodegenerative diseases and functional net-
works between miRNA and mRNA, which may lead to the
development of new generation of prognostic and diagnostic
markers and therapeutic intervention strategies for viral and
non-viral neurodegenerative diseases.
Conclusions
This study is the first report on whole-genome joint
mRNA and miRNA profile analysis from individual na-
tive brain tissue from HIV+ patients with and without
dementia and it underscores the important role of in-
trinsic functional correlation between mRNA-miRNA,
which is closely tied to HIV-mediated neurodegenera-
tion. Through mRNA and miRNA joint profiling this
study has provided the first thorough in vivo evidence
on the genomic basis of HIV-mediated neurodegenera-
tion and its correlation with miRNA. This provided a
firm support to intrinsic functional relationship that
exists between mRNA and miRNA in guiding neurode-
generation in HIV-infected brains. From the concord-
ance between miRNA and mRNA, it demonstrates the
significant involvement of axon guidance and its down-
stream signalling pathways in HIV-mediated neurode-
generation and development of HAD. Most importantly,
the most significant dysregulated and highly biological
relevant 3 miRNAs identified here, miR-137, 153 and
218, cumulatively targeted the axon guidance pathway as
well as its downstream signalling pathways, which may
find potential use as diagnostic/prognostic biomarkers
and for developing new generation of therapeutic inter-




Brain tissue samples were obtained from HIV-1-infected
patients with or without dementia through the NationalNeuro-AIDS Tissue Consortium (NNTC, Request #
R203) and the Westmead Hospital, Sydney, Australia
(Reference No: 5465). Samples were collected at post-
mortem with short delay. The autopsied brain tissue was
snap frozen in liquid nitrogen and stored at −80°C until
required for use. Frontal cortex of 10 male patients with
HAD and 8 without were used for this study due to its
importance in motor impairment and involvement in
other neurodegenerative disorders, such as: AD [77,78].
The average age for HAD and non-HAD patients was
51.88 ± 9.45 and 43.57 ± 14.77, respectively, (P =0.23).
Clinical profiles of all patients are shown in Additional
14. In order to make sure the quality of RNA, samples’
post mortem intervals were less than 48 hours have been
selected for the study. Among them, 5 samples from
HAD and HIV non-dementia group, respectively, have
been randomly chosen for miRNA study. This study was
conducted according to the principles expressed in the
Declaration of Helsinki. Use of samples in this study was
approved by the Institutional Review Board and the Eth-
ics Committee of the NNTC Allocations, the University
of Sydney and the Westmead Hospital individually. The
family members of the patients gave written, informed
consent for the use of autopsied brain tissue. For the
diagnostic criteria for HAD, the criteria defined by the
American Academy of Neurology 1991 were used [79].
RNA isolation and mRNA and miRNA profiling
Total RNA was extracted from 30 mg of brain cortex
tissue. Tissue samples were homogenised using a high-
speed agitation polytron belnder (Kinematica, Luzern,
Switzerland) in the presence of RNA lysis buffer (Qiagen
miRNeasy Mini kit- Qiagen, USA). The RNA was iso-
lated and purified with a miRNeasy Mini kit with DNAse
I digestion on the column (Qiagen, USA) according to
the manufacturer’s protocol. The quality and quantitiy of
the RNA preparations was assessed using an Agilent
2100 Bioanalyser (Agilent Technologies, USA). RNA in-
tegrity scores were>7 for all the samples analyzed. First-
Choice Human Brain Reference commercially available
RNA (Ambion, Inc., USA) was used as a control RNA
for the microarray analysis.
For mRNA profiling, cRNA amplification and labeling
with biotin were performed using Illumina TotalPrep
RNA amplification kit according to the manufacturer’s
directions (Ambion, USA) with 500ng total RNA as input
material. cRNA yields were quantified using Agilent 2100
Bioanalyser. Gene expression analysis was performed
using the Sentrix Human-6 v2 Expression BeadChip
(Illumina, USA), and BeadStation system from Illumina as
per manufacturer’s instructions. The Human-6 v2 Expres-
sion BeadChip allows genome-wide expression profiling of
more than 48,000 gene transcripts and known alternative
splice variants from the RefSeq database. For miRNA
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Biotin HSR RNA Labeling Kit (Genisphere Inc. USA) and
analzed using Affymetrix GeneChip miRNA Array
(Genisphere Inc. USA), which contains 1105 Homo
sapiens miRNAs.
Gene expression data analysis was performed using
GenomeStudio version 3 (Illumina Inc., Singapore). The
gene expression data was normalised using the cubic
spline function, the genes were selected if the detection
P<0.01 (indicating the transcript was detected) in at least
one group. All samples were coded and analyzed blindly
to avoid any bias. The differential gene expression analysis
was performed using Illumina custom error model with
false discovery rate correction implemented in GenomeS-
tudio [80]. Genes, whose DiffScore >13 or <−13 (corre-
sponding to significance level of P<0.05), were considered
statistically significant. miRNA data analysis was carried
out using GeneSpring 11.0 (Agilent Technologies, USA).
The data was normalised by expression percentile and
analysed using Mann–Whitney unpaired test. P<0.05 were
considered statistically significant.Real time quantitative RT-PCR validation of mRNA
and miRNA
The data for mRNA and miRNA were selectively corro-
borated with real-time PCR to ascertain their expression
trends. For mRNA, 5ng total RNA was reverse tran-
scribed using oligo d(T) and Superscript III followed by
RNase H treatment (Invitrogen Life Technologies), per
manufacturer’s instructions. PCR primers (Additional file
15) were designed for all the 11 genes selected on the
basis of the microarray data (Additional file 1) as well as
for the control genes (GAPDH: glyceraldehyde-3-
phosphate dehydrogenase), using the online software
Primer 3 (http://frodo.wi.mit.edu/primer3/). All primer
pairs were optimized to ensure the specific amplification
and the absence of any primer dimer. Quantitative PCR
standard curves were set up for all. The cDNA was then
subjected to real time quantitative PCR with defined pri-
mers and SYBR Green (Invitrogen Life Technologies)
using Mx3000p Stratagene real-time thermal cycler
(Stratagene, La Jolla, CA, USA). The data were analysed
using the MxPro™ QPCR software version 4.0.1 (Strata-
gene, La Jolla, CA, USA). For miRNA, expression levels
of six DE miRNAs (miR-153, 218, 19a, 216b, 122, 299-
5p and 280) were validated by quantitative real time RT-
PCR using the Qiagen miScript PCR system (Qiagen,
Valencia, CA, USA) according to the manufacture’s
protocol. Hs_RNU6B_3 was used as the endogenous
control to normalize the data. All the experiements were
performed in duplicate and relative expression levels of
these mRNAs/miRNAs were determined by the 2-ΔΔCt
method. The data then were further analysed by Studentt-test to check the statistical significance between HAD
and HIV non-dementia patients brains (P<0.05).
Transfection of microRNA mimic
SH-SY5Y cultures were maintained as confluent mono-
layers at 37°C with 5% CO2 and 90% humidity in SH-
SY5Y media (DMEM with 10% (vol/vol) foetal calf
serum, 20 mM HEPES, 2 mM L-glutamine). For differ-
entiation cells were seeded at 4 × 104 cells/cm2 and trea-
ted with all-trans retinoic acid (ATRA) media (SH-SY5Y
media with 10uM ATRA) for five days, followed by
treatment in brain-derived neurotrophic factor (BDNF)
media for three days (SH-SY5Y media without foetal calf
serum and with 50 ng/ml BDNF) [81]. Cells were then
harvested and nucleofected using Amaxa Nucleofector Kit
V (Lonza) according to manufacturer’s instructions. Each
nucleofection contained 4 × 106 cells and 0.1 nmol miR-
137 (T:[Phos]UUAUUGCUUAAGAAUACGCGUAG B:
[mA][mC]GCGUAUUCUUAAGCAAUAG[dT] [dT]) or
mirVanaTM miRNA mimic Negative Control #1, with
experiments performed in duplicate. Nucleofected cells
were seeded at 5 × 104/cm2 in BDNF media and grown
for 24 hrs before being harvested with TRIzol and RNA
isolated as described [82].
Functional validation of proteins using western blot
Western blot was employed to validate part of the
microarray data. 4 HAD patients and 4 HIV non-
dementia patients’ brain samples were used for valid-
ation of the microarray study by western blot analysis.
Total cellular proteins were extracted as described be-
fore [34]. 40 μg proteins were separated by 12% SDS-
polyacrylamide gels and then transferred to PVDF
membranes (Millipore, USA) or nitrocellulose mem-
branes (Amersham, USA) using Bio-Rad apparatus
(Bio-Rad, USA). Membranes were blocked in 5% skim
milk powder or 5% BSA in tris-buffered saline (TBS)
(20 mM Tris and 0.9% NaCl, pH 7.4) for 1 hour at
room temperature. Following that, they were incubated
for 2 hours at room temperature with each of the fol-
lowing primary antibodies: Rabbit anti-MEK2 (1:2000)
and JNK1 (1:1000) (Santa Cruz. USA). Mouse anti-
Actin (1:6000, DAKO, USA) was used as control anti-
body. Membranes were washed four times with TTBS
(TBS with 0.05% Tween20) and then incubated for 1
hour with anti-rabbit or anti-mouse HRP-conjugated
secondary antibody (Dako, USA; 1:6000) followed by
chemiluminescence ECL detection (GE, USA) and ex-
posure to autoradiography film (Kodak, France). Films
were scanned with HP scanjet8200 (HP, USA) and the
images were collected and analysed using ImageJ soft-
ware (http://rsbweb.nih.gov/ij/). Statistically significant
differences between patients were estimated with the
Student t-test (P<0.05).
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For mRNA, gene ontology analysis has been carried
out using DAVID and GSEA. Illumina ID of differential
expressed genes was uploaded to the DAVID database
and the analysis was performed using the algorithm
within the softwares. With GSEA, the whole genome
(27455 genes) with expression value were uploaded to
the software and compared with catalog C5 gene ontol-
ogy gene sets in MsigDB [29], which contains 233 GO
cellular component gene sets, 825 GO biological
process gene sets, 396 GO molecular function gene
sets. For miRNA, TargetScan was used to find the glo-
bal target of DE miRNAs, which were dysregulated by
at least two fold and the target gene list was uploaded
to DAVID as well. mRNA and miRNA correlation ana-
lysis has been performed using SA-BNs.Additional files
Additional file 1: Table S1. DE gene list.
Additional file 2: Figure S1. Hierarchical clustering analysis of global
mRNA and miRNA profiles obtained from the frontal cortex tissue at
autopsy of HIV patients with and without dementia. Pearson correlation
algorithm was chosen to evaluate and visualize the mRNA and miRNA
expression patterns using GenomeStudio v3 and GeneSpring respectively.
A. mRNA clustering. HAD samples are highlighted with (red square), and
HIV negative control samples are highlighted with (sky-blue square) while
HIV positive non-dementia patient samples are highlighted with (green
square). B miRNA clustering.
Additional file 3: Table S2. DE miRNA list.
Additional file 4: Figure S2. Target of hsa-miR-137.
Additional file 5: Table S3. Low and high stringency G-seed search for
miR-137, miR-153 and miR-218 targets.
Additional file 6: Table S4: Gene sets significantly enriched by GSEA
analysis.
Additional file 7: Table S5. Validation of non-changed miRNA.
Additional file 8: Figure S3. Significantly dysregulated genes on long
term potentiation pathway in HAD brains compared to HIV non-
dementia brains.
Additional file 9: Figure S4. Western blot validation of MAP2K2 and
MAP2K4. MAP2K2 and MAP2K4 encoding proteins MEK2 (A) and JNK (B)
with relative molecular weight 45 and 46kD respectively were separated
on 12% SDSpolyacrylamide gel and blotting with specific antibodies
against them. Semiquantitative analysis has been carried out by
comparing the relative protein level (standardized by Actin (C)) in HAD
and HIV non-dementia patients. The quantification result demonstrated
the trend similar to the one observed in microarray and qPCR for HAD
patients when compared to HIV non-dementia patients.
Additional file 10: Figure S5. Significantly dysregulated genes on
calcium signalling pathway in HAD brains compared to HIV non-
dementia brains.
Additional file 11: Figure S6. Significantly dysregulated genes on Jak-
STAT signalling pathway in HAD brains compared to HIV non-dementia
brains.
Additional file 12: Figure S7. Significantly dysregulated genes on VEGF
signalling pathway in HAD brains compared to HIV non-dementia brains.
Additional file 13: Table S6. DE miRNAs and their target pathways.
Additional file 14: Table S7. Patient details.
Additional file 15: Table S8. qPCR primers.Competing interests
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